

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/165442 A1

(51) International Patent Classification:

C07K 14/195 (2006.01) *C12N 9/22* (2006.01)
C07K 14/21 (2006.01) *C12N 9/96* (2006.01)
C07K 14/24 (2006.01) *C12N 15/62* (2006.01)
C07K 14/245 (2006.01) *A61K 38/16* (2006.01)
C07K 14/255 (2006.01) *A61K 38/46* (2006.01)
C07K 14/26 (2006.01) *A61P 31/04* (2006.01)
C07K 14/265 (2006.01)

(21) International Application Number:

PCT/EP2024/052628

(22) International Filing Date:

02 February 2024 (02.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2301639.7 06 February 2023 (06.02.2023) GB

(71) Applicants: **THE UNIVERSITY COURT OF THE**

UNIVERSITY OF GLASGOW [GB/GB]; The Gilbert
Scott Building, University Avenue, Glasgow G12 8QQ
(GB). **THE CHANCELLOR, MASTERS AND SCHOL-
ARS OF THE UNIVERSITY OF OXFORD** [GB/GB];
Wellington Square, Oxford Oxfordshire OX1 2JD (GB).

(72) Inventors: **WALKER, Daniel**; Strathclyde Institute of

Pharmacy & Biomedical Sciences (SIPBS), 161 Cathedral
Street, Glasgow G4 0RE (GB). **MOSBAHI, Khedidja**;
Strathclyde Institute of Pharmacy & Biomedical Sciences
(SIPBS), 161 Cathedral Street, Glasgow G4 0RE (GB).
KLEANTHOUS, Kleanthis; Department of Biochemistry,
University of Oxford, South Parks Road, Oxford Oxford-
shire OX1 3QU (GB). **HOUSDEN, Nicholas George**; De-
partment of Biochemistry, University of Oxford, South
Parks Road, Oxford Oxfordshire OX1 3QU (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(54) Title: ANTI-BACTERIAL PROTEIN COMPLEX




Figure 1

(57) **Abstract:** The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE